1.. Introduction
================

Epigenetic silencing of tumor suppressor genes (TSGs) including breast cancer susceptibility gene 1 (*BRCA1*), human MutL homolog 1 (*hMLH1*), *p16^INK4A^* and *p14^ARF^* involves DNA methylation maintained by DNA methyltransferase 1 (DNMT1), histone deacetylation and methylation through histone deacetylase 1 (HDAC1) and histone H3K9 methyltransferase G9a respectively ([@b1-ol-0-0-7290]--[@b3-ol-0-0-7290]). Ensuring a coordinated crosstalk between DNA methylation and histone deacetylation and methylation, ubiquitin-like containing plant homeodomain (PHD) and really interesting new gene domain (RING) finger domains 1 (UHRF1) overexpressed in various human cancer cells induces epigenetic silencing in several TSGs ([@b4-ol-0-0-7290]). UHRF1-mediated epigenetic silencing of TSG is primarily due to the presence of the SET- and RING-associated (SRA) domain ([@b4-ol-0-0-7290]). Through the SRA domain, UHRF1 interacts with HDAC1 and DNMT1 ([Fig. 1](#f1-ol-0-0-7290){ref-type="fig"}), leading to the inhibition of several TSGs including *p16^INK4A^, p14^ARF^* and retinoic acid receptor α ([@b1-ol-0-0-7290],[@b3-ol-0-0-7290],[@b5-ol-0-0-7290],[@b6-ol-0-0-7290]). Furthermore, the UHRF1 structure includes other functional domains which contribute to its inhibitory activity on TSGs including the ubiquitin-like domain, tandem Tudor domain (TTD), PHD and RING domain ([Fig. 1](#f1-ol-0-0-7290){ref-type="fig"}). A large macromolecular protein complex termed epigenetic code replication machinery (ECREM) is formed through interactions between the different UHRF1 domains and several epigenetic coordinators including HDAC1, DNMT1, histone acetyltransferase, Tat-interacting protein 60 (Tip60), herpesvirus-associated ubiquitin specific protease (HAUSP) and histone methyltransferase G9a and Suv39H1 ([Fig. 1](#f1-ol-0-0-7290){ref-type="fig"}) ([@b7-ol-0-0-7290]--[@b9-ol-0-0-7290]).

The ECREM complex is considered to be orchestrated by UHRF1 to ensure a coordinated transmission of silenced TSGs to daughter cells during cell division ([@b4-ol-0-0-7290],[@b7-ol-0-0-7290],[@b9-ol-0-0-7290]). UHRF1 binds to H3K9me2, a repressive chromatin mark, thus providing additional evidence of UHRF1-mediated crosstalk between DNA methylation and histone modification ([@b10-ol-0-0-7290]). Furthermore, UHRF1 was also demonstrated to bind to H3K9me3 through the TTD domain, an interaction involved in the regulation of p16^INK4A^ expression ([@b11-ol-0-0-7290]). Although overexpression of wild-type UHRF1 induced *p16^INK4A^* downregulation, such an effect was not demonstrated when the TTD-mutated UHRF1 variant was overexpressed, thus indicating that UHRF1 binding to H3K9me3 through the TTD domain is involved in the silencing of *p16^INK4A^* ([@b11-ol-0-0-7290]). In the same context, UHRF1 was demonstrated to use its PHD domain to specifically bind to H3K9me3 ([@b12-ol-0-0-7290]) and cause large-scale modifications of chromocenters which assisted in the recruitment of HDAC1 and DNMT1, and led to the formation of pericentromeric heterochromatin ([@b13-ol-0-0-7290]). The UHRF1, through its RING domain, was demonstrated to possess E3 ubiquitin ligase activity for histone 3, and was also involved in tumor proliferation; however, the role of this domain remains unclear ([@b14-ol-0-0-7290],[@b15-ol-0-0-7290]). UHRF1 interacts with HAUSP ([Fig. 1](#f1-ol-0-0-7290){ref-type="fig"}), a deubiquitinating enzyme involved in the regulation of several TSGs ([@b16-ol-0-0-7290]). HAUSP protects UHRF1 from its own E3 ligase activity (autoubiquitination), suggesting that UHRF1 uses its RING domain to target itself for degradation via autoubiquitination in response to the downregulation of HAUSP ([@b17-ol-0-0-7290]--[@b19-ol-0-0-7290]).

Collectively, these previous studies demonstrate that UHRF1 through its several functional domains negatively regulates the expression of TSGs via its interaction with numerous proteins. Thus, the inhibition of the expression and/or activity of UHRF1 may enable cancer cells to undergo apoptosis by reactivating TSGs. As UHRF1 belongs to a large macromolecular complex, in which it serves a function of a hub protein for the integration of epigenetic information, microRNAs (miRNAs) which target UHRF1 may have marked effects on cellular functions. In the present review, the role of these specific miRNAs in the regulation of UHRF1 ([Table I](#tI-ol-0-0-7290){ref-type="table"}), and the associated downstream events, as well as the importance of targeting miRNA/UHRF1 pathways as a novel strategy in cancer therapy, are discussed.

2.. Role of UHRF1 in carcinogenesis
===================================

Several previous studies indicate that UHRF1 may be a key regulator of the human epigenome through interactions with domains in several types of coordinator ([@b7-ol-0-0-7290],[@b20-ol-0-0-7290]--[@b23-ol-0-0-7290]). These interactions indicate that UHRF1 is involved in carcinogenesis through two key mechanisms. The first is regarded as a participation in the onset phase of cancer, whereas the second is with regard to the maintenance of the cancer phenotype. Concerning the first, the driving of DNA hypomethylation is a result of defective DNMT1-UHRF1 interaction ([@b24-ol-0-0-7290],[@b25-ol-0-0-7290]). The second is associated with the maintenance of DNA methylation patterns, particularly the hypermethylation of the TSG promoters and genome-wide hypomethylation ([@b6-ol-0-0-7290]).

Although the role of UHRF1 as a potent oncogene is well-documented in several solid tumors and hematological malignancies, its downregulation has been demonstrated to increase the malignancy of carcinoma cells through the activation of epithelial-mesenchymal transition (EMT) ([@b3-ol-0-0-7290],[@b4-ol-0-0-7290],[@b26-ol-0-0-7290]--[@b35-ol-0-0-7290]). Numerous types of human cancer including leukemia, breast, bladder, gastric, colorectal and astrocytoma express increased levels of UHRF1, causing an increase in cell proliferation, migration, metastasis and inhibition of apoptosis ([@b7-ol-0-0-7290],[@b36-ol-0-0-7290]--[@b39-ol-0-0-7290]). The UHRF1 serves a crucial function in the progression of the cell cycle at G~1~/S phase through the *p16^INK4A^*-dependent pathway, and its downregulation allows cancer cells to undergo apoptosis through DNA demethylation and histone deacetylation-dependent reactivation of several TSGs including *p16^INK4A^, BRCA1*, homeobox protein CDX-2 (*CDX2*), runt-related transcription factor 3 (*RUNX3*), forkhead box protein O4, peroxisome-proliferator-activated receptor γ and promyelocytic leukemia (*PML*) ([@b2-ol-0-0-7290],[@b32-ol-0-0-7290],[@b40-ol-0-0-7290]). UHRF1 overexpression in cancer cells, compared with matched normal tissue was suggested to be a potential biomarker for the prognosis and diagnosis of several types of cancer including bladder and colorectal carcinoma ([@b23-ol-0-0-7290],[@b36-ol-0-0-7290],[@b39-ol-0-0-7290]). Considering that cancer cells overexpress UHRF1, deciphering the upstream pathways involved in UHRF1 may shed light on the underlying molecular mechanisms involved in the silencing of TSGs in tumorigenesis.

3.. Role of miRNAs in cancer
============================

High-throughput transcriptome analysis demonstrated that the majority of transcriptional outcome is non-coding RNAs ([@b41-ol-0-0-7290]). These non-coding RNAs are classified, based on their length, into small non-coding RNAs (\<200 nucleotides), including miRNA, and long non-coding RNA (\>200 nucleotides), including nuclear paraspeckle assembly transcript 1 ([@b42-ol-0-0-7290],[@b43-ol-0-0-7290]). A number of non-coding RNAs have potential transcriptional, post-transcriptional and epigenetic regulatory functions, and are often dysregulated in many types of disease including cancer ([@b44-ol-0-0-7290]--[@b47-ol-0-0-7290]). miRNAs (18--25 nucleotides) are the most studied class of non-coding RNAs and post-transcriptionally regulate mRNA stability and translation ([@b48-ol-0-0-7290]). The biogenesis of miRNA and the mechanism by which they degrade mRNA and inhibit RNA translation is complex ([@b49-ol-0-0-7290]). Altered miRNA expression has been observed in many types of cancer cell line, xenograft, blood and clinical tissue ([@b50-ol-0-0-7290],[@b51-ol-0-0-7290]). Aberrant levels of miRNAs contribute to cancer formation and progression by regulating expression levels of key genes involved in tumorigenesis pathways which are responsible for cell proliferation, tumor migration, invasion, integrin-mediated adhesion, EMT and resistance to cancer therapy ([@b52-ol-0-0-7290]). Similar to protein-coding genes, miRNAs are also subject to epigenetic regulatory modifications in cancer ([@b53-ol-0-0-7290],[@b54-ol-0-0-7290]). The majority of miRNA loci are associated with CpG islands suggesting marked dependence on DNA methylation.

In cancer, miRNAs are able to function as being either oncogenic or a tumor suppressor, depending on the target gene ([@b55-ol-0-0-7290]). For example, miR-21 was the first miRNA to be identified as being oncogenic, and was demonstrated to be overexpressed in numerous types of cancer ([@b56-ol-0-0-7290]). Mechanistically, miR-21 was observed to suppress the expression of many TSGs, including phosphatase and tensin homolog, programmed cell death protein 4 and sprout 1 (*SPRY1*) ([@b57-ol-0-0-7290],[@b58-ol-0-0-7290]). However, miR-34b, miR-199b and miR-218 are examples of tumor suppressor miRNAs that were observed to be downregulated in several types of tumor ([@b59-ol-0-0-7290],[@b60-ol-0-0-7290]). Advances in genomic technologies may lead to identification of novel miRNAs involved in cancer, therefore the increase in the understanding of their biological functions and target genes is expected to enhance our knowledge on the role of miRNA in cancer progression and permit the development of miRNA-associated cancer biomarkers and consequently the formation of effective therapy.

Considering the fact that numerous types of human cancer express increased levels of the oncogene UHRF1 in association with decreased expression levels of several tumor suppressor miRNAs, UHRF1 overexpression in cancer as a result of altered miRNA expression is a subject worth investigating ([@b36-ol-0-0-7290]). Nevertheless, it has previously been indicated that UHRF1 overexpression may also be a result of increased stability, and of the inhibitory effects of several miRNAs on its expression ([@b36-ol-0-0-7290]). However, it should be noted that UHRF1 has been demonstrated to be regulated by several other pathways including the cluster of differentiation 47/nuclear factor κB axis, TSG p53 and p73, and the thyroid hormone receptor α1/specificity protein 1 pathway ([@b61-ol-0-0-7290]--[@b64-ol-0-0-7290])

4.. Regulation of UHRF1 by miR-146a/b in gastric cancer
=======================================================

Several previous studies have demonstrated that UHRF1 is overexpressed in gastric cancer (GC) and therefore promote the invasion and metastasis of this type of cancer; however, the upstream regulatory mechanisms involved in UHRF1 overexpression are currently unknown ([@b32-ol-0-0-7290],[@b65-ol-0-0-7290],[@b66-ol-0-0-7290]). Increased levels of UHRF1 expression were identified in tissue samples from patients with GC compared with normal controls, and its overexpression was associated with patient age and lymph node metastasis ([@b66-ol-0-0-7290]). The levels of UHRF1 were also significantly increased in tissues isolated from patients with GC compared with corresponding normal tissues. Furthermore, increased expression levels of UHRF1 were identified in GC tissues in association with GC stage and grade ([@b65-ol-0-0-7290]). Similarly, UHRF1 was demonstrated to be overexpressed in GC, and its downregulation induced upregulation of several TSGs including *RUNX3, BRCA1* and *PML* through a promoter demethylation-dependent mechanism, inhibiting GC cell proliferation and metastasis ([@b32-ol-0-0-7290]). Furthermore, another study demonstrated that UHRF1 was overexpressed in tissues from patients with GC compared with matched normal tissues, and its increased expression levels were associated with GC metastases ([@b67-ol-0-0-7290]). Of note, UHRF1 depletion decreased GC migration and metastasis; however, overexpression significantly promoted these effects ([@b67-ol-0-0-7290]). Collectively, the results of these previous studies demonstrate that UHRF1 is a primary factor in GC development, and suggest that understanding the molecular mechanisms underlying UHRF1 overexpression in GC may assist in discovering the underlying molecular mechanisms involved in GC tumorigenesis.

miR-146a and miR-146b are known to act as tumor suppressors in several types of tumor including GC and lung cancer ([@b67-ol-0-0-7290]--[@b69-ol-0-0-7290]). It has been demonstrated that UHRF1 is regulated by miR-146a/b in GC ([@b67-ol-0-0-7290]). Furthermore, miR-146a/b overexpression significantly downregulated UHRF1 expression through directly targeting its 3′-untranslated region (UTR) ([@b67-ol-0-0-7290]). The downregulation was associated with DNA demethylation-dependent reactivation of a number of TSGs including Slit guidance ligand 3, cadherin 4 and *RUNX3*, and a decrease in GC cell migration and metastasis ([@b67-ol-0-0-7290]). Furthermore, the downregulation of miR-146a/b led to an increase in the expression of UHRF1, indicating that UHRF1 is negatively regulated by miR-146a/b in normal cells ([@b67-ol-0-0-7290]). A previous study also demonstrated that miR-146a binds to the 3′-UTR of UHRF1, providing additional evidence of a direct regulation of UHRF1 by miR-146a ([@b65-ol-0-0-7290]). Collectively, these results that support the hypothesis that UHRF1 mRNA is a direct target of miR-146a/b in GC, and miR-146a/b overexpression may be a promising strategy to downregulate UHRF1 in order to achieve GC metastasis inhibition through the reactivation of TSGs ([Fig. 2A](#f2-ol-0-0-7290){ref-type="fig"}).

5.. Regulation of UHRF1 by miRNAs in bladder cancer and kidney tumors
=====================================================================

Several previous studies have revealed the important role of UHRF1 in human bladder cancer (BC) invasion ([@b1-ol-0-0-7290],[@b70-ol-0-0-7290]--[@b72-ol-0-0-7290]). UHRF1 was demonstrated to be overexpressed in bladder and kidney cancer, and its increased expression levels were associated with the stage and grading of BC ([@b73-ol-0-0-7290]). UHRF1 expression was increased in BC compared with matched normal tissues, and its overexpression was associated with tumor grade, relapse and survival rate ([@b70-ol-0-0-7290]). Several underlying molecular mechanisms have been suggested to explain the contribution of UHRF1 in the pathology of BC; however, the molecular mechanisms underlying UHRF1 regulation in this type of tumor are largely unknown. UHRF1 was demonstrated to promote the invasion of BC through epigenetic silencing of the tumor suppressor kisspeptin (*KiSS1*) and the regulator of G-protein signaling 2 ([@b71-ol-0-0-7290],[@b72-ol-0-0-7290]). A recent study also reported that the overexpression of UHRF1 detected in BC tissues was accompanied by decreased levels of miR-124, acting as a tumor suppressor. Furthermore, miR-124 overexpression in human BC cells induced a decrease in UHRF1 expression, which led to the inhibition of cell proliferation, metastasis and invasion ([@b74-ol-0-0-7290]). Notably, a luciferase assay confirmed that miR-124 regulates UHRF1 expression by binding to the 3′-UTR of UHRF1, suggesting that UHRF1 overexpression observed in BC may be attributed at least in part to the loss of the expression of the tumor suppressor miR-124. The UHRF1 was recently demonstrated to be targeted in normal bladder cells by other tumor suppressor miRNAs including miR-145-5p and miR-145-3p ([@b75-ol-0-0-7290]). The downregulation of these miRNAs in BC causes overexpression of UHRF1 ([@b75-ol-0-0-7290]). Furthermore, this study demonstrated that BC expresses increased levels of UHRF1 compared with normal tissue, and its overexpression is associated with decreased levels of miR-145-5p and miR-145-3p. UHRF1 downregulation in BC cells induced a reactivation of a number of TSGs including PR domain zinc finger protein 2 (*PRDM2*), which acts as a histone methyltransferase on H3K9, and also led to the inhibition of several oncogenes including survivin (*BIRC5*) and centromere protein F (*CENPF*) ([@b75-ol-0-0-7290]--[@b77-ol-0-0-7290]). Notably, transfection of BC cells by miR-145-5p or miR-145-3p induced UHRF1 downregulation and consequently cell cycle arrest and apoptosis ([@b75-ol-0-0-7290]). Furthermore, luciferase reporter assays confirmed that miR-145-5p and miR-145-3p bind directly to different sites on 3′-UTR of UHRF1 ([@b75-ol-0-0-7290]). These results demonstrate that overexpression of miR-124, miR-145-5p and miR-145-3p in BC are able to decrease the expression levels of UHRF1, leading to BC metastasis inhibition by downregulating the anti-apoptotic proteins BIRC5 and CENPF ([Fig. 2B](#f2-ol-0-0-7290){ref-type="fig"}). Collectively, these results support that miRNAs regulate TSG expression through the control of UHRF1, which dictates the level of DNA methylation and histone H3 methylation levels via PRDM2 and/or G9a.

UHRF1 was also revealed to be overexpressed in clear cell renal cell carcinoma (ccRCC), which represents \~70% of all renal cell carcinomas (RCCs) ([@b73-ol-0-0-7290],[@b78-ol-0-0-7290],[@b79-ol-0-0-7290]). UHRF1 overexpression at the mRNA and protein levels in ccRCC was associated with the downregulation of the TSG *TP53* ([@b79-ol-0-0-7290]). This study demonstrated that UHRF1 directly binds to p53 protein causing ubiquitination-dependent degradation of p53, leading to apoptosis inhibition and ccRCC promotion ([@b79-ol-0-0-7290]). Recent studies have demonstrated that UHRF1 is overexpressed in primary and metastatic ccRCC tumors associated with decreased expression levels of miR-146a-5p, which has also been demonstrated to act as a tumor suppressor in non-small cell lung cancer (NSCLC) and prostate cancer ([@b78-ol-0-0-7290],[@b80-ol-0-0-7290],[@b81-ol-0-0-7290]). Notably, overexpression of miR-146a-5p in two different human kidney cancer cell lines (786-O and ACHN) significantly decreased the expression of UHRF1 ([@b78-ol-0-0-7290]). These results indicate that miR-146a-5p negatively regulates the expression of UHRF1 in ccRCC, and miR-146a-5p upregulation is sufficient to induce UHRF1 degradation and p53 reactivation leading to the inhibition of ccRCC progression ([Fig. 2C](#f2-ol-0-0-7290){ref-type="fig"}). The overexpression of miR-101, a tumor suppressor miRNA, was recently demonstrated to inhibit the expression of UHRF1 in RCC ([@b82-ol-0-0-7290]--[@b84-ol-0-0-7290]). Currently, it is not yet known whether UHRF1 is regulated by a unique miRNA in a cell-specific manner, or by several miRNAs within a same cell, and therefore further investigation is required.

6.. Regulation of UHRF1 by miR-9 in colorectal cancer
=====================================================

Several previous studies have demonstrated that UHRF1 is overexpressed in colorectal cancer (CRC) and induces epigenetic silencing of several TSGs including *p16^INK4A^* leading to cell growth and metastasis ([@b39-ol-0-0-7290],[@b85-ol-0-0-7290],[@b86-ol-0-0-7290]). CRC tissues and cell lines have exhibited overexpression of UHRF1 with decreased levels of p16^INK4A^ expression and increased metastasis ([@b39-ol-0-0-7290]). Conversely, UHRF1 downregulation induced an upregulation of p16^INK4A^, cell proliferation, migration inhibition, cell cycle arrest and apoptosis ([@b39-ol-0-0-7290]). In the same context, increased levels of UHRF1 were detected in specimens of CRC, and *in vitro* UHRF1 downregulation resulted in inhibition of CRC proliferation ([@b86-ol-0-0-7290]). Collectively, these studies indicate that UHRF1 overexpression may be a primary event in CRC development, and therefore its targeting may represent a novel approach to CRC therapy. However, the upstream factors which regulate UHRF1 expression in CRC remain unclear.

UHRF1 overexpression was associated with decreased survival rates of patients with CRC, and a decrease in the expression of the tumor suppressor miR-9 ([@b87-ol-0-0-7290]--[@b90-ol-0-0-7290]). The luciferase assay demonstrated that UHRF1 is directly regulated by miR-9, indicating that UHRF1 overexpression in CRC results from a decrease in miR-9 expression ([@b87-ol-0-0-7290]). Notably, miR-9 overexpression in CRC cells was able to significantly decrease UHRF1 expression and cell proliferation, and induce apoptosis ([Fig. 2D](#f2-ol-0-0-7290){ref-type="fig"}). These results demonstrate that another miRNA is involved in CRC compared with the aforementioned types of cancer. Thus, these results suggest a cell-specific dependence of UHRF1 regulation towards miRNAs.

7.. Regulation of UHRF1 by miR-193a-3p in NSCLC
===============================================

UHRF1 was also identified as being overexpressed in several other types of NSCLC, and may serve as a diagnostic and therapeutic marker for this type of cancer ([@b91-ol-0-0-7290]--[@b93-ol-0-0-7290]). Increased expression levels of UHRF1 were identified in primary NSCLC accompanied with increased levels of the three DNA methyltransferases DNMT1, DNMT3A and DNMT3B concomitantly with hypermethylation of several TSG promoters including cyclin-dependent kinase inhibitor 2 (*CDKN2A*) and Ras-associated domain-containing protein 1 (*RASSF1*) ([@b94-ol-0-0-7290]). Notably, UHRF1 depletion induced a promoter demethylation-dependent reactivation of *CDKN2A* and *RASSF1* with subsequent inhibition of cell proliferation and metastasis ([@b94-ol-0-0-7290]). These results suggest that UHRF1 overexpression is involved in the molecular pathogenesis of NSCLC and that the upstream regulatory mechanisms begin to be elucidated. Accordingly, miR-193a-3p serves as a tumor suppressor in cancer, and its overexpression was demonstrated to repress NSCLC progression ([@b95-ol-0-0-7290]). Recently, it has been identified that miR-193a-3p inhibits NSCLC metastasis by downregulating several oncogenes including UHRF1 ([Fig. 2E](#f2-ol-0-0-7290){ref-type="fig"}), suggesting that UHRF1 expression is inversely associated with miR-193a-3p in NSCLC ([@b93-ol-0-0-7290]). Furthermore, these studies collectively support the hypothesis that each type of cancer has a different type of UHRF1 in terms of miRNA.

8.. Conclusion
==============

The present review provides an insight into the molecular mechanism underlying how miRNAs may function as tumor suppressors by directly inhibiting the expression of the oncogene UHRF1 which is considered to be a master of the epigenetic silencing of several TSGs in cancer. It is also indicated that the combined expression of regulator miRNA and UHRF1 may be a potential diagnostic and prognostic marker in cancer. UHRF1 is overexpressed in several types of human cancer, which contributes to the increase in cell proliferation, metastasis and the inhibition of apoptosis. Considering the fact that abnormalities in miRNA expression may be a potent cause of cancer development, exploring the direct association between UHRF1 and miRNAs will increase our understanding of tumor pathology, and may also allow the development of novel therapeutic strategies based on specific targeting of the miRNA/UHRF1 pathways in several types of tumor ([Fig. 2](#f2-ol-0-0-7290){ref-type="fig"}). However, future investigations are required to understand the downregulation of miRNAs in the pathogenesis of cancer. Furthermore, the assessment of the cell-specific miRNA-dependent regulation of UHRF1 as well as the origin of the deregulation of these types of miRNA may also be required.
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![Schematic model of UHRF1 structure and its role in the regulation of the epigenetic code (DNA methylation and histone modifications). Through its SRA domain, UHRF1 interacts with DNMT1 and HDAC1. Using its PHD domain, UHRF1 may interact with the histone methyltransferase G9a and also with DNMT1. UHRF1 may be autoubiquitinated by its RING domain, encompassing an E3 ligase activity. By its interaction with HAUSP, UHRF1 may be protected from autoubiquitination. The TTD is involved in histone methylation reading with the subsequent recruitment of the histone methyltransferases G9a and Suv39H1. The UBL domain may be involved in the proteasome pathway. The question mark represents a putative interaction that requires further confirmation. SRA, SET- and RING-associated; DNMT1, DNA methyltransferase 1; HDAC1, histone deacetylase 1; PHD, plant homeodomain; RING, really interesting new gene; UHRF1, ubiquitin-like with PHD and RING finger domains 1; HUASP, herpesvirus-associated ubiquitin-specific protease; TTD, tandem Tudor domain; UBL, ubiquitin-like; Tip60, Tat-interacting protein 60; UB, ubiquitin.](ol-15-01-0003-g00){#f1-ol-0-0-7290}

![Schematic representation of the role of miRNA in UHRF1 regulation in different types of cancer cell: (A) Gastric cancer, (B) bladder cancer, (C) clear cell renal cell carcinoma, (D) colorectal cancer and (E) non-small cell lung cancer. Several tumor suppressor miRNAs are able to bind to the 3′-UTR of UHRF1 mRNA. This binding induces UHRF1 mRNA degradation and leads to the reactivation of several TSGs including *Slit3, CDH4, RUNX3, PRDM2* and *TP53* or to the inhibition of the expression of certain oncogenes including *BIRC5* and *CENPF*. Question marks indicate putative effects that require further confirmation. UHRF1, ubiquitin-like with PHD and RING finger domains 1; TSG, tumor suppressor gene; Slit3, slit homolog 3 protein; CHD4, cadherin 4; RUNX3, runt-related transcription factor 3; PRDM2, PR domain zinc finger protein 2; BIRC5, survivin; CENPF, centromere protein F; miR, microRNA.](ol-15-01-0003-g01){#f2-ol-0-0-7290}

###### 

Types of miRNA involved in UHRF1 regulation in various tumors and UHRF1-regulated genes.

  miRNA            Type of cancer   Function   Reported target genes of UHRF1   (Refs.)
  ---------------- ---------------- ---------- -------------------------------- ------------------------------------------
  146a/b           GC               TSG        TSGs: Slit3, CDH4 and RUNX3      ([@b67-ol-0-0-7290],[@b69-ol-0-0-7290])
  124              BC               TSG                                         ([@b74-ol-0-0-7290])
  145-5p, 145-3p   BC               TSG        Oncogenes: BIRC5 and CENPF       ([@b75-ol-0-0-7290])
  146a-5p          ccRCC            TSG        TSGs: p53?                       ([@b78-ol-0-0-7290])
  193a-3p          NSCLC            TSG        TSGs                             ([@b93-ol-0-0-7290],[@b95-ol-0-0-7290])
  101              RCC              TSG                                         ([@b84-ol-0-0-7290])
  9                CRC              TSG                                         ([@b87-ol-0-0-7290]--[@b89-ol-0-0-7290])

Question marks indicate putative effects that require further confirmation. miRNA, microRNA; GC, gastric cancer; BC, bladder cancer; ccRCC, clear cell renal cell carcinoma; RCC, renal cell carcinoma; NSCLC, non-small cell lung cancer; TSG, tumor suppressor gene; Slit3, slit homolog 3 protein; CHD4, cadherin 4; RUNX3, runt-related transcription factor 3; BIRC5, survivin; CENPF, centromere protein F.
